Drug Patents owned by Amicus Therap Us

1. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406143 AMICUS THERAP US Methods for treatment of fabry disease May, 2027

(4 years from now)

US9000011 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US9480682 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US9987263 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US10383864 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US11241422 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US9999618 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US11033538 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US10525045 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US10925866 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones Apr, 2028

(5 years from now)

US10813921 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

US9095584 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

US8592362 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

USRE48608 AMICUS THERAP US Method to predict response to pharmacological chaperone treatment of diseases Feb, 2029

(6 years from now)

US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene Mar, 2037

(14 years from now)

US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene Mar, 2037

(14 years from now)

US10849890 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10849889 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10857142 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10874657 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10874655 AMICUS THERAP US Methods of treating fabry patients having renal impairment May, 2038

(15 years from now)

US10874656 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10792278 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10792279 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10799491 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10806727 AMICUS THERAP US Methods of treating fabry patients having renal impairment May, 2038

(15 years from now)

US10251873 AMICUS THERAP US Methods of treating fabry patients having renal impairment May, 2038

(15 years from now)

US10471053 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

US10857141 AMICUS THERAP US Methods of treating Fabry patients having renal impairment May, 2038

(15 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients; A method of reducing podocyte globotriaosylceramide (gl-3) in a fabry patient by administering migalastat; a method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.